Many of you probably rounded on MRSA (methicillin resistant staph aureus) infected patients today in the hospital who are undergoing medical and surgical treatment for their infection. This previously rare antibiotic resistant infection was noted to become a growing nosocomial and community infection in the mid 1980's. MRSA now comprises up to 75% of staph infections in many regional hospitals and this has caused significant alarm in the infectious disease community since drug therapies remain limited.

Dr. Snyder presents a thorough discussion of the emerging medical concern of MRSA and new trends on the best practice for treatment of these infections in the lower extremity. He points out many reasons why hospitals and healthcare personnel have been responsible for the increased prevalence of MRSA infections and some pointers as to how you can help avoid this.

Several case discussions help to give a real world understanding of MRSA and its affect on our patients. The emerging po treatment option of linezolid is presented as an alternative to long term IV Vancomycin. Costs, delivery, efficacy, and patient compliance are examined in relation to successful MRSA treatment.

CLICK IMAGE BELOW TO VIEW LECTURE